1,5-Anhydroglucitol (GlycoMark™) as a marker of short-term glycemic control and glycemic excursions

Expert Review of Molecular Diagnostics

Volumn 8, Issue 1, 2008, Pages 9-19

  Dungan, Kathleen M ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

1,5 anhydroglucitol; A1C; Glucose; Glycemic control; Glycemic excursion; Glycemic variability; Post prandial glucose

Indexed keywords

1,5 ANHYDROSORBITOL; ANTIDIABETIC AGENT; FRUCTOSAMINE; HEMOGLOBIN A1C; INSULIN; SULFONYLUREA; TROGLITAZONE; VOGLIBOSE; 1,5-ANHYDROGLUCITOL; BIOLOGICAL MARKER; DEOXYGLUCOSE; UNCLASSIFIED DRUG;

CHEMICAL STRUCTURE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PREGNANCY; REVIEW; SCREENING; TREATMENT OUTCOME; URINARY EXCRETION; BLOOD; DIABETES MELLITUS; POSTPRANDIAL STATE;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; DEOXYGLUCOSE; DIABETES MELLITUS; HUMANS; POSTPRANDIAL PERIOD;

EID: 38149030947     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.8.1.9     Document Type: Review

References (93)

1. The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of Type 1 diabetes mellitus. JAMA 287, 2563-2569 (2002).
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 352 (9131), 837-853 (1998).
3. American Diabetes Association: Standards of medical care in diabetes - 2007. Diabetes Care 30, S4-S41 (2007).
4. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281(21), 2005-2012 (1999).
5. Malik S, Lopez V, Chen R, Wu W, Wong ND. Undertreatment of cardiovascular risk factors among persons with diabetes in the United States. Diabetes Res. Clin. Pract. 77(1), 126-133 (2007).
6. Shojania KG, Ranji SR, McDonald KM et al. Effects of quality improvement strategies for type 2 diabetes on glycemic control: a meta-regression analysis. JAMA 296, 427-440 (2006).
7. Pogach L, Engelgau M, Aron David MD. Measuring progress toward achieving hemoglobin A1c goals in diabetes care: pass/fail or partial credit. JAMA 297(5), 520-523 (2007).
8. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann. Intern. Med. 141(6), 413-420 (2004).
9. DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortalitiy: comparison of fasting and 2-hour diagnostic criteria. Arch. Intern. Med. 161, 397-405 (2001).
10. Hanefeld M, Fischer S, Julius U et al.; DIS Group. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39, 1577-1583 (1996).
11. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidatie stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 52(11), 2795-2804 (2003).
12. Inhat M, Green D, Ross K et al. Reduced antioxidant response of retinal and endothelial cells in response to chronic oscillating glucose levels. Diabetes 54(Suppl. 1), 2314 (2005).
13. Risso A, Mrecuri F, Quagliaro L, Damante G, Ceriello A. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am. J. Physiol. Endocrinol. Metab. 281, 924-930 (2001).
14. Monnier L, Mas E, Ginet C et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with Type 2 diabetes. JAMA 295(14), 1681-1687 (2006).
15. Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in Type 2 diabetes mellitus. Circulation 110, 214-219 (2004).
16. The Diabetes control and Complications Trial (DCCT) Research Group. The relationship between glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complicatioins Trial. Diabetes 44, 968-983 (1995).
17. Schwedes U, Siebolds M, Mertes G; for the SMBG Study Group. Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated Type 2 diabetic patients. Diabetes Care 25, 1928-1932 (2002).
18. Guerci B, Drouin P, Grangé V et al.; for the ASIA group. Self-monitoring of blood glucose significantly improves metabolic control in patients with Type 2 diabetes mellitus: the Auto-Surveillance Intervention Active (ASIA) study. Diabetes Metab.29, 587-594 (2003).
19. Karter AJ, Parker MM, Moffet HH et al. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care 29(8), 1757-1763 (2006).
20. Martin S, Schneider B, Heinemann L et al.; for the ROSSO Study Group Self-monitoring of blood glucose in Type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia 49, 271-278 (2006).
21. Gerich J, Odawara M, Terauchi Y. The rationale for paired pre-and postprandial self-monitoring of blood glucose: the role of glycemic variability in micro- and macrovascular risk. Curr. Med. Res. Opin. 23(8), 1791-1798 (2007).
22. Davidson J. Strategies for improving glycemic control: effective use of glucose monitoring. Am. J. Med. 118(Suppl. 9A), S27-S32 (2005).
23. Bergenstal R, Pearson J, Cembrowski GS, Bina D, Davidson J, List S. Identifying variables associated with inaccurate self-monitoring of blood glucose: proposed guidelines to improve accuracy. Diabetes Educ. 26(6), 81-89 (2000).
24. Raine CH III. Self-monitored blood glucose: a common pitfall. Endocr. Pract. 9(2), 137-139 (2003).
25. No authors listed. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial Research Group. N. Engl. J. Med. 329, 977-986 (1993).
26. Stratton IM, Adler AI, Neil HAW et al.; on behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. Br. Med. J. 321, 405-412 (2000).
27. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 44, 968-983 (1995).
28. Zhang L, Krzentowski G, Albert A, Lefebvre PJ. Risk of developing retinopathy in Diabetes Control and Complications Trial Type 1 diabetic patients with good or poor metabolic control. Diabetes Care 24(7),1275-1279 (2001).
29. Service JF, O'Brien PC. Influence of glycemic variables on hemoglobin A1C. Endocr. Pract. 13(4), 350-354 (2007).
30. Twomey PJ, Wierzbicki AS, Reynolds TM. Issues to consider when attempting to achieve the American Diabetes Association clinical quality requirement for haemoglobin A1c. Curr. Med. Res. Opin. 19(8), 719-723 (2003).
31. Phillipou G, Phillips PJ. Intraindividual variation of glycohemoglobin: implications for interpretation and analytical goals. Clin. Chem. 39, 2305-2308 (1993).
32. Tahara Y, Shima K. The response of GHb to stepwise plasma glucose change over time in diabetic patients. Diabetes Care 16, 1313-1314 (1993).
33. Derr R, Garrett E, Stacy GA, Saudek CD. Is HbA(1c) affected by glycemic instability? Diabetes Care 26, 2728-2733 (2003).
34. Saudek CD, Derr RL, Kalyani RR. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA 12, 295(14), 1688-1697 (2006).
35. Braatvedt GD, Drury PL, Cundy T. Assessing glycaemic control in diabetes: relationships between fructosamine and HbA1C. NZ Med. J. 12, 110(1057), 459-462 (1997).
36. Hom FG, Ettinger B, Lin MJ. Comparison of serum fructosamine vs glycohemoglobin as measures of glycemic control in a large diabetic population. Acta Diabetol. 35(1), 48-51 (1998).
37. Kunika K, Itakura M, Yamashita K. Correction of fructosamine value for serum albumin and globulin concentrations. Diabetes Res. Clin. Pract. 13(1-2), 37-44 (1991).
38. Lindsey CC, Carter AW, Mangum S et al. A prospective, randomized, multicentered controlled trial to compare the annual glycemic and quality outcomes of patients with diabetes mellitus monitored with weekly fructosamine testing versus usual care. Diabetes Technol. Ther. 6(3), 370-377 (2004).
39. Garg S, Zisser H, Schwartz S et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care 29(1), 44-50 (2006).
40. Deiss D, Bolinder J, Riveline JP et al. Improved glycemic control in poorly controlled patients with Type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care 29(12), 2730-2732 (2006).
41. Klonoff DC. A review of continuous glucose monitoring technology. Diab. Technol. Ther. 7(5), 770-775 (2005).
42. Wilson DM, Block J. Real-time continuous glucose monitor use and patient selection: what have we learned and where are we going? Diab. Technol. Ther. 7(5), 788-791 (2005).
43. Larsen J, Ford T, Lyden E, Colling C, Mack-Shipman L, Lane J. What is hypoglycemia in patients with well-controlled Type 1 diabetes treated by subcutaneous insulin pump with use of the continuous glucose monitoring system? Endocr. Pract. 10 (4), 324-329 (2004).
44. Hanaire H. Continuous glucose monitoring and external insulin pump: towards a subcutaneous closed loop. Diabetes Metab. 32(5 Pt 2), 534-538 (2006).
45. Yamanouchi T, Tachibana Y, Akanuma H et al. Origin and disposal of 1,5-anhydroglucitol, a major polyol in the human body. Am. J. Physiol. 263(2 Pt 1), E268-E273 (1992)
46. Yamanouchi T, Akanuma Y. Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control. Diab. Res. Clin. Pract. 24 (Suppl.), S261-S268 (1994).
47. Yamanouchi T, Shinohara T, Ogata N, Tachibana Y, Akaoka I, Miyashita H. Common reabsorption system of 1,5-anhydro-D-glucitol, fructose, and mannose in rat renal tubule. Biochim. Biophys. Acta.1291(1), 89-95 (1996).
48. +-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose. Life Sci. 76(9), 1039-1050 (2005).
49. Akanuma Y, Morita M, Fukuzawa N, Yamanouchi T, Akanuma H. Urinary excretion of 1,5-anhydro-D-glucitol accompanying glucose excretion in diabetic patients. Diabetologia 31(11), 831-835 (1988).
50. Yamanouchi T, Kawasaki T, Funato H et al. Plasma 1,5-anhydro-D-glucitol as a new clinical marker of glycemic control in NIDDM patients. Diabetes 38, 723-729, (1989).
51. Stickle D, Turk J. A kinetic mass balance model for 1,5-anhydroglucitol: applications to monitoring of glycemic control. Am. J. Physiol. 273(4 Pt 1), E821-E830 (1997).
52. Yamanouchi T, Inoue T, Ichiyanagi K, Sakai T, Ogata N. 1,5-anhydroglucitol stimulates insulin release in insulinoma cell lines. Biochim. Biophys. Acta. 1623(2-3), 82-87 (2003).
53. Nowatzke W, Sarno MJ, Birch NC, Stickle DF, Eden T, Cole TG. Evaluation of an assay for serum 1,5-anhydroglucitol (GlycoMark™) and determination of reference intervals on the Hitachi 917 analyzer. Clin. Chim Acta. 350(1-2), 201-209 (2004).
54. Fukumura Y, Tajima S, Oshitani S et al. Fully enzymatic method for determining 1,5-anhydro-D-glucitol in serum. Clin. Chem. 40, 2013-2016 (1994).
55. Yoshioka S, Saitoh S, Fujisawa T, Fujimore AA, Takatani O, Funabashi M. Identification and metabolic implication of 1-deoxyglucose (1,5-anhydroglucitol) in human plasma. Clin. Chem. 28(6), 1283-1286 (1982).
56. Niwa T, Yamamoto N, Maeda K, Yamada K, Ohki T, Mori M. Gas chromatographic-mass spectrometric analysis of polyols in urine and serum of uremic patients. Identification of new deoxyalditols and inositol isomers. J. Chromatogr. 277, 25-39 (1983).
57. Buse JB, Freeman JL, Edelman SV, Jovanovic L, McGill JB. Serum 1,5-anhydroglucitol (GlycoMark): a short-term glycemic marker. Diabetes Technol. Ther. 5(3), 355-363 (2003).
58. Yamanouchi T, Akanuma H, Asano T, Konishi C, Akaoka I, Akanuma Y. Reduction and recovery of plasma 1,5-anhydro-D-glucitol level in diabetes mellitus. Diabetes 36(6), 709-715 (1987).
59. McGill JB, Cole TG, Nowatzke W et al.; U.S. trial of the GlycoMark assay. Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. Diabetes Care 27(8), 1859-1865 (2004). •• Demonstrates that 1,5-anhydroglucitol (1,5-AG) reflects short-term changes in glycemic control better than hemoglobin A1C (A1C) or fructosamine.
60. Kawasaki T, Yamanouchi T, Kashiwabara A et al. The influence of traditional Chinese herbal drugs on serum 1,5-anhydroglucitol levels. Diab. Res. Clin. Pract. 50(2), 97-101 (2000).
61. Watanabe K, Uchino H, Ohmura C, Tanaka Y, Onuma T, Kawamori R. Different effectsof two α-glucosidase inhibitors, acarbose and voglibose, on serum 1,5-anhydroglucitol (1,5AG) level. J. Diabetes Complicat. 18, 183-186 (2004).
62. Yamanouchi T, Akanuma H, Nakamura T, Akaoka I, Akanuma Y. Reduction of plasma 1,5-anhydroglucitol (1-deoxyglucose) concentration in diabetic patients. Diabetologia 31, 41-45 (1988).
63. Yamanouchi T, Ogata N, Tagaya T et al. Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. Lancet 347, 1514-1518 (1996). • Demonstrates that changes in 1,5-AG more closely reflect recent changes in glycemic control than do A1C or fructosamine.
64. Sekino N, Kashiwabara A, Inoue T et al. Usefulness of troglitazone administration to obese hyperglycaemic patients with near-normoglycemia. Diab. Obes. Metab. 5, 145-149 (2003).
65. Yamanouchi T, Moromizato H, Shinohara T, Minoda S, Miyashita H, Akaoka I. Estimation of plasma glucose fluctuation with a combination test of A1C and 1,5-AG. Metabolism 41(8), 862-867 (1992). • Findings in this study show that 1,5-AG reflects glycemic variability even in patients with similar A1C values, and that 1,5-AG improves with therapies that target glycemic variability.
66. Kishimoto M, Yamasaki Y, Kubota M et al. 1,5-anhydro-D- glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care 18(8), 1156-1159 (1995). •• Demonstrates that 1,5-AG is improved with more physiologic insulin regimens and that 1,5-AG, but not A1C, correlated with glycemic variability.
67. Matsumoto K, Yano M, Miyake S et al. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes Care 21(2), 256-260, (1998).
68. Dworacka M, Winiarska H. The application of plasma 1,5-anhydro-D-glucitol for monitoring type 2 diabetic patients. Dis. Markers. 21(3), 127-132 (2005). • The study indicates that 1,5-AG is closely associated with maximal daily glucose values whereas A1C more closely approximates fasting glucose. A1C may be similar over a broad range of 1,5-AG values.
69. Salardi S, Zucchini S, Santoni R et al. The glucose area under the profiles obtained with continuous glucose monitoring system relationships with HbA1c in pediatric Type 1 diabetic patients. Diabetes Care 25, 1840-1844 (2002).
70. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 30(2), 263-269 (2007).
71. Dungan K, Buse J, Largay J. 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 29, 1214-1219 (2006). • This study identified 1,5-AG as a marker of glycemic control that is superior to A1C or fructosamine for identifying postprandial hyperglycemia.
72. Dungan K, Buse J, Largay J, Wittlin S. 1,5-anhydroglucitol (1,5-AG) and postprandial hyperglycemia as measured by continuous glucose monitoring system (CGMS) in inadequately controlled patients with diabetes. European Association for the Study of Diabetes (EASD) Annual Meeting (2005) (Abstract 719).
73. Kawasaki I, Sato I, Hosoi M et al. Serum 1,5-anhydroglucitol is a strong predictor of the postprandial hyperglycemia in Type 2 diabetes patients (Abstract). Diabetes 54(Suppl. 1), A76 (2005).
74. Akutsu T, Mori Y, Itoh Y, Tajima N. 1,5-anhydroglucitol and postprandial hyperglycemia as assessed by self-monitoring of blood glucose in Japanese patients with moderately controlled diabetes. American Diabetes Association 67th Annual Scientific Sessions. (2007) (Abstract 0423-P).
75. Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, Kawasaki T. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. Diab. Med. 22, 980-985 (2005).
76. Frias JP, Button E, Lush C, Brunelle R, Yamanouchi T. 1,5-anhydroglucitol, a PPG excursion marker in pramlintide treated subjects. American Association of Clinical Endocrinologists Annual Meeting (2007) (Abstract 296).
77. Kendall D, Button E, Blasé E et al. Exenatide improves postprandial glucose (PPG) control in patients with Type 2 diabetes, as measured by 1,5-anhydroglucitol (Glycomark). American Diabetes Association 67th Annual Scientific Sessions. (2007) (Abstract 2211-P).
78. Nonaka K, Kakikawa T, Sato A et al. Twelve-week efficacy and tolerability of sitagliptin, a dipeptidyl peptidase (DPP-4) inhibitor, in Japanese patients with T2DM. American Diabetes Association 66th Annual Scientific Sessions. (2006) (Abstract 537-P).
79. Moses A, Raskin P, Hu P, Allen E. Serum 1,5-anhydroglucitol as a marker of glycemic control in subjects receiving twice-daily biphasic insulin aspart 70/30 (BIAsp 70/30) vs. Once-Daily Insulin Glargine in Patients with Type 2 DM on Oral Antidiabetic Agents. American Diabetes Association 65th Annual Scientific Sessions. (2005) (Abstract 392-P).
80. Yamanouchi T, Akanuma Y, Toyota T et al. Comparison of 1,5-anhydroglucitol, HbA1c, and fructosamine for detection of diabetes mellitus. Diabetes 40(1), 52-57 (1991).
81. Yamanouchi T, Inoue T, Ogata E et al. Post-load glucose measurements in oral glucose tolerance tests correlate well with 1,5-anhydroglucitol, an indicator of overall glycaemic state, in subjects with impaired glucose tolerance. Clin. Sci. 101(3), 227-233, (2001).
82. Robertson DA, Alberti KG, Dowse GK, Zimmet P, Tuomilehto J, Gareeboo H. Is serum anhydroglucitol an alternative to the oral glucose tolerance test for diabetes screening? The Mauritius noncommunicable diseases study group. Diabet. Med. 10(1), 56-60 (1993).
83. de Veciana M, Major CA, Morgan MA et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N. Engl. J. Med. 333(19), 1237-1241 (1995).
84. Kilpatrick ES, Keevilt BG, Richmond KL, Newland P, Addison GM. Plasma 1,5-anhydroglucitol concentrations are influenced by variations in the renal threshold for glucose. Diabet. Med. 16(6), 496-499 (1999).
85. Dworacka M, Wender-Ozegowska E, Winiarska H et al. Plasma anhydro-D-glucitol (1,5-AG) as an indicator of hyperglycaemic excursions in pregnant women with diabetes. Diabet. Med. 23(2), 171-175 (2006). • The authors report that 1,5-AG is independently associated with maximum daily glucose and glucose variability.
86. Nguyen TM, Rodriguez LM, Mason KJ, Heptulla RA. Serum 1,5-anhydroglucitol (Glycomark) levels in children with and without type 1 diabetes mellitus. Pediatr. Diabetes 8(4), 214-219 (2007).
87. American Diabetes Association. Standards of medical care in diabetes - 2006. Diabetes Care 29, S4-S42 (2006).
88. The American College of Endocrinology Task Force on Inpatient Diabetes and Metabolic Control. American College of Endocrinology position statement on inpatient diabetes and metabolic control. Endocr. Pract. 10(1), 77-82 (2004).
89. Dworacka M, Winiarska H, Magdalena M, Wierusz-Wysocka B. Stress-induced hyperglycemia monitored by serum 1,5-anhydroglucitol (GlycoMark™) as a short-term glycemic marker. American Diabetes Association 64th Annual Scientific Sessions. (2004) (Abstract 1929-PO).
90. Yamada H, Hishida A, Kato A, Yoneyama T. 1,5-anhydroglucitol as a marker for the differential diagnosis of acute and chronic renal failure. Nephron 73(4), 707-709 (1996).
91. Dworacka M, Winiarska H, Borowska M, Abramczyk M, Bobkiewicz-Kozlowska T, Dworacki G. Pro-atherogenic alterations in T-lymphocyte subpopulations related to acute hyperglycaemia in Type 2 diabetic patients. Circ. J. 71, 962-967 (2007).
92. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler. Thromb, Vasc. Biol. 21, 1876-1890 ( 2001).
93. Ceriello A, Colagiuri S, Gerich J et al. International Diabetes Federation. Guideline for management of postprandial glucose 2007 www.idf.org/webdata/docs/Guideline_PMG_final.pdf